PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8654074

Corticosteroid allergy.

S Freeman
View original source ↗Export metadata ↓

Abstract

Allergy to corticosteroids is becoming increasingly recognized. Diagnosis is difficult because of frequently false-negative patch tests. The optimum concentration and vehicle for patch testing with pure corticosteroid has still not been established. The patch test results of 19 patients with allergy to corticosteroids seen at the Skin and Cancer Foundation in Sydney, Australia, were analysed. It was found that patch testing with the patient's corticosteroid in the commercial cream base gave a greater yield of positive results than testing with the commercial corticosteroid ointment or with the pure corticosteroid in either petrolatum or in alcohol. Tixocortol pivalate, and to a lesser extent budesonide, were useful for detecting allergy to hydrocortisone, but not necessarily other corticosteroids. Delayed positive patch tests were often seen, showing the importance of carrying out a late reading. The repeat open application test (ROAT) with the patient's own corticosteroid was found to be a simple, useful diagnostic test.

Explore related subjects

Adrenal Cortex HormonesDermatitis, Allergic ContactHumansPatch TestsRetrospective StudiesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Freeman. 1995. Corticosteroid allergy.. https://doi.org/10.1111/j.1600-0536.1995.tb00474.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗
PubMed2007

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗